SAN JOSE, Calif., March 12, 2026
PROCEPT BioRobotics has announced the international launch of its HYDROS® Robotic System, a next-generation AI-enabled surgical platform designed to deliver Aquablation® therapy for the treatment of benign prostatic hyperplasia (BPH). The launch marks a significant milestone for the company as it expands access to robot-assisted, minimally invasive treatment for prostate enlargement, a condition affecting millions of men globally. The United Kingdom will serve as the first international market for the HYDROS robotic platform, with further international expansion planned throughout 2026.
The technology integrates artificial intelligence, real-time ultrasound imaging, and robotic surgical precision, enabling physicians to perform personalized and anatomy-specific treatment planning while maintaining consistent procedural outcomes. The introduction of this advanced system reflects the growing adoption of AI-driven surgical robotics in urology, offering patients improved symptom relief and quality-of-life outcomes through innovative treatment technology.
AI-Enabled Robotic Platform Improves Precision Surgery
The HYDROS Robotic System represents the next evolution of robotic surgical technology for urology, combining AI-interpreted ultrasound imaging with advanced image-guided treatment planning to assist surgeons during prostate procedures.
Through real-time imaging and AI-supported visualization, surgeons can precisely map prostate anatomy and determine the exact areas of tissue that require removal before the robotic procedure begins. Once the treatment plan is finalized, the robotic system executes the therapy using Aquablation technology, a heat-free waterjet designed to remove excess prostate tissue with exceptional accuracy.
Advertisement
Unlike traditional surgical methods that rely on heat-based technologies such as laser or electrocautery, Aquablation therapy uses robot-guided water pressure to remove obstructive prostate tissue while preserving surrounding structures responsible for urinary continence and sexual function. This advanced approach allows surgeons to maintain high procedural precision and reproducibility, reducing variability between procedures while improving surgical outcomes. The platform is specifically designed to enable scalable adoption across healthcare settings, ensuring that hospitals and surgical centers can integrate robotic prostate surgery while maintaining consistent treatment quality.
Addressing the Global Burden of Benign Prostatic Hyperplasia
Benign prostatic hyperplasia is one of the most common urological diseases affecting aging men, causing symptoms such as frequent urination, weak urine flow, bladder pressure, and disrupted sleep patterns. Globally, the condition impacts tens of millions of men and is often associated with lower urinary tract symptoms (LUTS) that significantly affect daily activities and quality of life.
Many patients remain on long-term medications or delay surgical treatment due to concerns about potential side effects or complications, including sexual dysfunction or incontinence. Aquablation therapy has emerged as a promising alternative treatment because it provides durable symptom relief while preserving critical anatomical functions.
The therapy utilizes robotic precision guided by ultrasound imaging, allowing surgeons to perform targeted tissue removal tailored to each patient’s unique prostate anatomy. Clinical research supporting Aquablation therapy has demonstrated consistent improvement in urinary symptoms and durable treatment outcomes, helping to position the technology as an innovative solution for managing BPH.
Expanding Global Access to Robotic Urology Innovation
The international rollout of the HYDROS platform reflects PROCEPT BioRobotics’ long-term strategy to expand access to robotic surgical technologies across global healthcare systems. By introducing AI-powered treatment planning and robotic execution, the system allows physicians to combine clinical expertise with advanced digital tools to deliver more precise prostate treatments.
According to the company, the technology builds upon a strong clinical evidence base for Aquablation therapy, supported by approximately 250 peer-reviewed scientific publications demonstrating its safety, effectiveness, and durable patient outcomes. The company also develops the AQUABEAM® robotic system, which works alongside the HYDROS platform to support Aquablation procedures.
As healthcare providers increasingly adopt robotic and AI-driven surgical technologies, the HYDROS system is expected to play a crucial role in modernizing prostate surgery and improving treatment options for men suffering from BPH worldwide. With the UK serving as the first international market and further global expansion planned, PROCEPT BioRobotics aims to make robot-assisted Aquablation therapy more widely accessible, delivering safer and more consistent surgical outcomes for patients across multiple healthcare environments.
Source: PROCEPT BioRobotics press release
